Cargando…

Towards a population-based threshold of protection for COVID-19 vaccines

Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG anti-Spike antibodies were highly correlated with ID50 neutralization in a validated p...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldblatt, David, Fiore-Gartland, Andrew, Johnson, Marina, Hunt, Adam, Bengt, Christopher, Zavadska, Dace, Snipe, Hilda Darta, Brown, Jeremy S., Workman, Lesley, Zar, Heather J., Montefiori, David, Shen, Xiaoying, Dull, Peter, Plotkin, Stanley, Siber, George, Ambrosino, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673730/
https://www.ncbi.nlm.nih.gov/pubmed/34933765
http://dx.doi.org/10.1016/j.vaccine.2021.12.006
_version_ 1784615511378624512
author Goldblatt, David
Fiore-Gartland, Andrew
Johnson, Marina
Hunt, Adam
Bengt, Christopher
Zavadska, Dace
Snipe, Hilda Darta
Brown, Jeremy S.
Workman, Lesley
Zar, Heather J.
Montefiori, David
Shen, Xiaoying
Dull, Peter
Plotkin, Stanley
Siber, George
Ambrosino, Donna
author_facet Goldblatt, David
Fiore-Gartland, Andrew
Johnson, Marina
Hunt, Adam
Bengt, Christopher
Zavadska, Dace
Snipe, Hilda Darta
Brown, Jeremy S.
Workman, Lesley
Zar, Heather J.
Montefiori, David
Shen, Xiaoying
Dull, Peter
Plotkin, Stanley
Siber, George
Ambrosino, Donna
author_sort Goldblatt, David
collection PubMed
description Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG anti-Spike antibodies were highly correlated with ID50 neutralization in a validated pseudoviral assay and correlated significantly with efficacies for protection against infection with wild-type, alpha and delta variant SARS-CoV-2 virus. The protective threshold for each vaccine was calculated for IgG anti-Spike antibody. The mean protective threshold for all vaccine studies for WT virus was 154 BAU/ml (95 %CI 42–559), and for studies with antibody distributions that enabled precise estimation of thresholds (i.e. leaving out 2-dose mRNA regimens) was 60 BAU/ml (95 %CI 35–102). We propose that the proportion of individuals with responses above the appropriate protective threshold together with the geometric mean concentration can be used in comparative non-inferiority studies with licensed vaccines to ensure that new vaccines will be efficacious.
format Online
Article
Text
id pubmed-8673730
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-86737302021-12-16 Towards a population-based threshold of protection for COVID-19 vaccines Goldblatt, David Fiore-Gartland, Andrew Johnson, Marina Hunt, Adam Bengt, Christopher Zavadska, Dace Snipe, Hilda Darta Brown, Jeremy S. Workman, Lesley Zar, Heather J. Montefiori, David Shen, Xiaoying Dull, Peter Plotkin, Stanley Siber, George Ambrosino, Donna Vaccine Article Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG anti-Spike antibodies were highly correlated with ID50 neutralization in a validated pseudoviral assay and correlated significantly with efficacies for protection against infection with wild-type, alpha and delta variant SARS-CoV-2 virus. The protective threshold for each vaccine was calculated for IgG anti-Spike antibody. The mean protective threshold for all vaccine studies for WT virus was 154 BAU/ml (95 %CI 42–559), and for studies with antibody distributions that enabled precise estimation of thresholds (i.e. leaving out 2-dose mRNA regimens) was 60 BAU/ml (95 %CI 35–102). We propose that the proportion of individuals with responses above the appropriate protective threshold together with the geometric mean concentration can be used in comparative non-inferiority studies with licensed vaccines to ensure that new vaccines will be efficacious. The Author(s). Published by Elsevier Ltd. 2022-01-21 2021-12-15 /pmc/articles/PMC8673730/ /pubmed/34933765 http://dx.doi.org/10.1016/j.vaccine.2021.12.006 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Goldblatt, David
Fiore-Gartland, Andrew
Johnson, Marina
Hunt, Adam
Bengt, Christopher
Zavadska, Dace
Snipe, Hilda Darta
Brown, Jeremy S.
Workman, Lesley
Zar, Heather J.
Montefiori, David
Shen, Xiaoying
Dull, Peter
Plotkin, Stanley
Siber, George
Ambrosino, Donna
Towards a population-based threshold of protection for COVID-19 vaccines
title Towards a population-based threshold of protection for COVID-19 vaccines
title_full Towards a population-based threshold of protection for COVID-19 vaccines
title_fullStr Towards a population-based threshold of protection for COVID-19 vaccines
title_full_unstemmed Towards a population-based threshold of protection for COVID-19 vaccines
title_short Towards a population-based threshold of protection for COVID-19 vaccines
title_sort towards a population-based threshold of protection for covid-19 vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673730/
https://www.ncbi.nlm.nih.gov/pubmed/34933765
http://dx.doi.org/10.1016/j.vaccine.2021.12.006
work_keys_str_mv AT goldblattdavid towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT fioregartlandandrew towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT johnsonmarina towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT huntadam towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT bengtchristopher towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT zavadskadace towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT snipehildadarta towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT brownjeremys towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT workmanlesley towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT zarheatherj towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT montefioridavid towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT shenxiaoying towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT dullpeter towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT plotkinstanley towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT sibergeorge towardsapopulationbasedthresholdofprotectionforcovid19vaccines
AT ambrosinodonna towardsapopulationbasedthresholdofprotectionforcovid19vaccines